These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34343846)

  • 1. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.
    Wei S; Han Y; Zeng H; Ye S; Cheng J; Chai F; Wei J; Zhang J; Hong N; Bao Y; Zhou J; Ye Y; Meng X; Zhou Y; Deng Y; Qiu M; Tian J; Wang Y
    Eur J Radiol; 2021 Sep; 142():109863. PubMed ID: 34343846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method.
    Cheng J; Wei J; Tong T; Sheng W; Zhang Y; Han Y; Gu D; Hong N; Ye Y; Tian J; Wang Y
    Ann Surg Oncol; 2019 Dec; 26(13):4587-4598. PubMed ID: 31605342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
    Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
    AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
    [No Abstract]   [Full Text] [Related]  

  • 5. Prediction of transformation in the histopathological growth pattern of colorectal liver metastases after chemotherapy using CT-based radiomics.
    Wei S; Gou X; Zhang Y; Cui J; Liu X; Hong N; Sheng W; Cheng J; Wang Y
    Clin Exp Metastasis; 2024 Apr; 41(2):143-154. PubMed ID: 38416301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of histopathological growth pattern in predicting 3-year progression free survival after operation in patients with liver metastasis of colorectal cancer].
    Zhang YL; He HJ; Cheng J; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jan; 50(1):26-31. PubMed ID: 33396983
    [No Abstract]   [Full Text] [Related]  

  • 7. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
    Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer.
    Bohlok A; Tonneau C; Vankerckhove S; Craciun L; Lucidi V; Bouazza F; Hendlisz A; Van Laethem JL; Larsimont D; Vermeulen P; Donckier V; Demetter P
    Clin Exp Metastasis; 2023 Oct; 40(5):431-440. PubMed ID: 37453024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.
    Mazard T; Mollevi C; Loyer EM; Léger J; Chautard R; Bouché O; Borg C; Armand-Dujardin P; Bleuzen A; Assenat E; Lecomte T
    Cancer Imaging; 2024 Jun; 24(1):77. PubMed ID: 38886836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
    Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
    Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
    Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases.
    Wei J; Cheng J; Gu D; Chai F; Hong N; Wang Y; Tian J
    Med Phys; 2021 Jan; 48(1):513-522. PubMed ID: 33119899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
    Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
    Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy.
    Ye S; Han Y; Pan X; Niu K; Liao Y; Meng X
    Front Oncol; 2022; 12():843991. PubMed ID: 35692757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
    Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.